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OBJECTIVES: To calculate an exact cost of tyrosinaemia type 1
in Poland. METHODS: A retrospective medical documentation
search and analysis was performed supplemented by information
obtained from families. The project covered eight patients aged
2,5–12,5, treated conservatively in Poland according to interna-
tional standards in year 2006. The analysis was performed from
societal perspective. All direct medical, non-medical and indirect
costs were included. In addition a questionnaire measuring
comfort of life of ill children’s parents was applied. RESULTS:
A mean direct cost was calculated to be €56,096.64
(189 045.66 PLN) per patient. The division of cost groups was as
follows: pharmacotherapy 86.5%, special diet 9.5%, hospital-
ization 2.5%, diagnostic tests 1% and transportation 0.5%. The
indirect costs were €3277.4 (11,044.94 PLN) per patient. In this
group resignation from work accounted for 94%, cost of addi-
tional care 5.5% and cost of complications 0.5%. The total
yearly cost per patient was €59,374.18 (200 090.6 PLN) and the
cost of illness in absolute terms was estimated at the level of
€474,993.4 (1,600,727.70 PLN). A signiﬁcant decrease of life
quality was observed in all families with child suffering from
tyrosinaemia type 1 included in this study. CONCLUSIONS:
Despite a small number of diagnosed and alive Polish patients
with tyrosinaemia type 1, as orphan disease—the condition is a
substantial problem of medical, economic and social nature. Ex
rate €1 = 3.37 PLN (20.06.2008).
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OBJECTIVES: to analyze prospectively the effect of adding Pre-
gabalin (PGB) on health care and non-health care resources
utilization (HRU) and related costs evolution in the treatment of
refractory Neck Pain under routine medical practice conditions.
METHODS: Post-hoc analysis of a sample of patients above 18
years, with 6-month chronic Neck Pain refractory to, at least,
one previous analgesic, included in a prospective, naturalistic,
12-weeks two-visit study. This analysis compared patients receiv-
ing PGB as an add-on therapy (PGB add-on) versus subjects
receiving any other analgesic pattern not including PGB (non-
PGB). Health care resources included all-type medical visits,
hospitalizations, complementary tests and pharmacological/
non-pharmacological therapies. Non-health care included wages
loses due to loss-workdays equivalents (LWDE = absenteeism
days + days working with reduced productivity due to pain).
RESULTS: A total of 312 [65.3% women, 54.2 (12.1) years]
patients were analyzed: 78.2% received PGB add-on and 21.8%
non-PGB. Twelve weeks therapy with PGB add-on was associ-
ated with higher reduction in pain severity than in non-PGB
yielding to a greater reduction in mean LWDE: 20.1 (23.1) vs. 8.2
(22.4); p = 0.014, which produced higher signiﬁcant reductions
in the indirect component of costs: €1041.0 (1222.8) vs. €457.3
(1,132.1), p = 0.028. The extra costs of PGB [€309.8 (193.2) vs.
€26.4 (79.6), p < 0.001], was off-set by higher numerical reduc-
tions in the other component of health care costs producing
similar direct cost reductions in both groups at the end of the
study: €66.8 (1080.8) and €143.5 (1922.4), respectively;
p = 0.295. CONCLUSIONS: Compared with adding other any
drug, the addition of PGB to the treatment pattern of refractory
Neck Pain was associated with higher lost work-day equivalent
reduction which was translated into higher reduction in the
indirect component of cost while maintaining similar level of
health care costs despite the higher price of pregabalin.
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OBJECTIVES: to analyze prospectively the effect of adding
Pregabalin (PGB) on health care and non-health care resources
utilization (HRU) and related costs evolution in the treatment of
refractory Low Back Pain (LBP) under routine medical practice
conditions. METHODS: Post-hoc analysis of a sample of
patients above 18 years, with 6-month chronic LBP refractory
to, at least, one previous analgesic, included in a prospective,
naturalistic, 12-weeks two-visit study. This analysis compared
patients receiving PGB as an add-on therapy (PGB add-on) versus
subjects receiving any other analgesic pattern not including PGB
(non-PGB). HRU included all-type medical visits, hospitaliza-
tions, complementary tests, and all-types treatments. Non-health
care included wages loses due to loss-workdays equivalents
(LWDE = absenteeism days + days working with reduced pro-
ductivity). RESULTS: Six hundred eighty-three patients [49.5%
women, 55.0 (12.7) years] were analyzed: 82.6% received PGB
add-on and 17.4% non-PGB. Twelve weeks therapy with PGB
add-on was associated with higher reduction in pain severity
than in non-PGB yielding to a greater reductions in mean LWDE:
19.1 (23.4) days vs. 12.0 (22.0); p = 0.002, which produced
higher reduction in the indirect component of costs: €961.8
(1242.9) vs. €625.8 (1169.2), p = 0.004. The extra cost of PGB
[€303.8 (175.8) vs. €37.1 (97.0), p < 0.001], was off-set by
reductions in the other components of health care costs pro-
ducing similar cost reductions in both groups at the end of the
study: €29.7 (999.2) and €46.5 (1925.3), respectively; p = 0.540.
Overall, PGB add-on therapy was associated with higher total
cost reduction: €991.5 (1702.3) vs. €579.3 (2410.3); p = 0.023.
CONCLUSIONS: Compared with adding other any drug, the
addition of PGB to the treatment pattern of refractory Low Back
Pain was associated with higher lost work-day equivalent reduc-
tion which was translated into higher reduction in the indirect
component and in total costs while maintaining similar level of
health care costs despite the higher price of pregabalin.
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